Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HTR6 | P50406 | 5/20 | 0.51 |
| ▸ | PHGDH | O43175 | 1/20 | 0.49 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.49 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | UQCRB | P14927 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13028543 | 0.89 | IKBKB (0.68) | IKBKBPOLBALDH1A1HTR6PHGDH | |
| SCHEMBL2889311 | 0.89 | IKBKB (0.67) | IKBKBPOLBALDH1A1HTR6PHGDH | |
| SCHEMBL13028501 | 0.86 | CYP19A1 (0.66) | IKBKBPOLBALDH1A1HTR6PHGDH | |
| SCHEMBL13028493 | 0.86 | IKBKB (0.64) | IKBKBPOLBALDH1A1HTR6PHGDH | |
| SCHEMBL13028510 | 0.86 | IKBKB (0.64) | IKBKBPOLBALDH1A1HTR6PHGDH | |
| SCHEMBL2888719 | 0.86 | IKBKB (0.64) | IKBKBPOLBALDH1A1HTR6PHGDH | |
| SCHEMBL2896582 | 0.85 | IKBKB (0.62) | IKBKBMEN1PKMKMT2A | |
| SCHEMBL13067966 | 0.83 | IKBKB (0.71) | IKBKBPOLBALDH1A1HTR6PHGDH | |
| SCHEMBL14425657 | 0.83 | HTR6 (0.72) | IKBKBPOLBALDH1A1HTR6PHGDH | |
| SCHEMBL6973491 | 0.82 | IKBKB (0.69) | IKBKBALDH1A1HTR6CYP19A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137141-B1 | BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | UNIV ABERDEEN (GB) | 2015-12-02 | — | — | EP | disclosed |
| EP-2137141-B1 | BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | UNIV ABERDEEN (GB) | 2015-12-02 | — | — | EP | disclosed |
| US-8524778-B2 | Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents | PIMCO 2664 LIMITED (GB) | 2013-09-03 | — | — | US | disclosed |
| US-8524778-B2 | Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents | PIMCO 2664 LIMITED (GB) | 2013-09-03 | — | — | US | disclosed |
| US-8524778-B2 | Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents | PIMCO 2664 LIMITED (GB) | 2013-09-03 | — | — | US | disclosed |
| US-20100286266-A1 | Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286266-A1 | Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286266-A1 | Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2010-11-11 | — | — | US | disclosed |
| EP-2137141-A1 | BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | The University Court of The University of Aberdeen (GB) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008114022-A1 | BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008114022-A1 | BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286266-A1 | Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents | ARSA, SOST, AHR | IKBKB 139/4885POLB 3123/4885ALDH1A1 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.